Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of JNJ-54861911 with Rosuvastatin and Metformin
NCT02611518Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2016
- Primary completion
- Jun 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of atabecestat in Alzheimer's disease (AD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Time and 1 more. Started Apr 2016; status: completed.
02
Drugs
atabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02611518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02611518.